Cross-tissue machine learning prioritizes a 13-gene rheumatoid-arthritis activity score
A machine-learning feature-selection pipeline integrated public whole-blood (1,885 samples) and synovial-tissue (284 samples) transcriptomic datasets and selected a 13-gene rheumatoid-arthritis score. Across five independent transcriptomic datasets, the score tracked DAS28 disease activity, distinguished rheumatoid arthritis from osteoarthritis, separated polyarticular juvenile idiopathic arthritis from healthy controls, and was associated with treatment effects. In an independent immunoblot cohort, two of six tested proteins, TNFAIP6/TSG-6 and HSP90AB1/HSP90, were confirmed.
Technology: Cross-tissue machine-learning feature-selection pipeline for transcriptomic data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent immunoblot cohort, two of six tested proteins, TNFAIP6/TSG-6 and HSP90AB1/HSP90, were confirmed.
- Still unknown: The transcriptomic inputs were previously published datasets and the reported clinical associations are observational; the study does not establish a deployable diagnostic test or causal disease mechanism. The independent protein follow-up confirmed two of six proteins tested, not the entire 13-gene panel, and validation in larger prospective cohorts is needed. Treatment-effect association should not be interpreted as prospective prediction of individual response.
- AI role: The pipeline selected a compact 13-gene signature from public blood and synovial expression datasets; the study evaluated its association with disease activity and diagnostic distinctions across five independent transcriptomic datasets, then tested six selected proteins by immunoblot in a separate patient cohort.
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.638066/pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 47 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.